-
Ciprofloxacin Hydrochloride: Mechanism & Research Use
2026-09-18
Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Evidence supports its use as an antibacterial research compound and FDA-labeled inhalational anthrax treatment, while immunomodulatory findings remain model-dependent and preclinical.
-
VER 155008: HSP 70 Inhibitor Workflows
2026-09-18
Build a practical workflow around VER 155008, from Hsp70 ATPase target engagement to apoptosis and cancer cell proliferation assays. The guide also shows how to pair HSP70 inhibition with proteomic profiling, using the reference study to improve biomarker discovery while avoiding common solubility, exposure, and interpretation errors.
-
KX2-391 Dihydrochloride: Applied Workflows
2026-09-17
KX2-391 dihydrochloride connects Src-substrate inhibition with tubulin disruption, enabling mechanism-aware oncology screens rather than single-endpoint cytotoxicity assays. The same reagent also supports distinct HBV transcription and BoNT/A workflows when concentration ranges, controls, and orthogonal readouts are kept separate.
-
Puromycin in AAV Translation and Selection Strategy
2026-09-17
Puromycin dihydrochloride is more than a routine selectable reagent: it is a translation-level perturbation that can strengthen how engineered AAV capsids are validated. This thought-leadership guide connects pac-based selection, ribosome biology, and the nanobody-directed AAV tropism study to help translational researchers separate vector entry, expression, and cellular fitness.
-
Cefotaxime as a Lens on Resistance Assays
2026-09-16
Cefotaxime can do more than inhibit bacterial growth: it can help researchers connect resistance genotype, mobile-element biology, and phenotype. This evidence-led guide shows how to use the third-generation cephalosporin antibiotic in antimicrobial resistance research without overinterpreting susceptibility data.
-
L. plantarum DS0037 ELNs: Senolytic and Senomorphic Effects
2026-09-16
This 2024 study identifies exosome-like nanovesicles from Lactobacillus plantarum DS0037 as a microbial-derived candidate with both senolytic and senomorphic activity. The vesicles preferentially reduced senescent-cell viability, moderated inflammatory and matrix-remodeling markers, and produced early improvements in skin-elasticity-related measures, although the evidence remains primarily preclinical and model-dependent.
-
Nirmatrelvir: A 3CLpro Assay Interpretation Guide
2026-09-15
Nirmatrelvir (PF-07321332) is examined through a decision-focused framework for linking 3CLpro inhibition to SARS-CoV-2 replication biology. This guide emphasizes assay interpretation, orthogonal controls, compound handling, and the practical limits of docking-based evidence.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-15
A high-throughput biochemical screen of approximately 6,000 compounds identified merbromin as a selective inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease, 3CLpro. Kinetic, binding, and docking analyses supported a mixed-type mechanism involving two binding sites, providing a mechanistic starting point for antiviral inhibitor development.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-14
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination experiments further show that RTK inhibition can increase temozolomide-associated toxicity, supporting ATRX status as a useful stratification variable in translational studies rather than as a standalone clinical biomarker.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-09-14
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen inclusion complex formation and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly those containing aromatic or phenyl groups. This dossier-based guidance supports pharmaceutical and biochemical workflows, but it does not establish compound-specific therapeutic efficacy, clinical bioavailability, or performance outside those applications.
-
ABT-888 (Veliparib) Workflow for DNA Damage Studies
2026-09-13
ABT-888 (Veliparib) offers a practical way to probe PARP1/2-dependent DNA repair inhibition and sensitize cancer models to chemotherapy or radiation. This workflow connects colorectal cancer research and MSI tumor models with replication-stress biology, including the biomarker insights of recent ovarian cancer research.
-
Clarithromycin as a CYP3A Inhibitor
2026-09-12
Clarithromycin is a macrolide antibiotic and CYP3A inhibitor used in drug-drug interaction research and pharmacokinetic studies. Its defined solvent profile, storage requirement, and CYP3A-centered mechanism support controlled enzyme and exposure experiments, but they do not replace clinical interaction assessment.
-
ER-Targeting Peptide Self-Assembly in Cancer
2026-09-11
This study develops an alkaline-phosphatase-instructed peptide that combines p-toluenesulfonamide-mediated endoplasmic reticulum targeting with enzyme-instructed self-assembly. The resulting assemblies selectively accumulate in ALP-rich cancer cells, induce ER stress and dysfunction, and promote apoptosis and necroptosis at lower effective concentrations than a non-targeted intracellular strategy.
-
Phylloquinone Protects Neurons from OGD Ferroptosis
2026-09-11
The reference study identifies phylloquinone as a neuroprotective compound that reduces oxygen-glucose deprivation-induced neuronal injury by suppressing ferroptosis through the xCT/GPX4 pathway. Its findings connect ferroptosis control with reduced oxidative damage and cellular senescence, while positioning Klf2 as a potential mechanistic mediator requiring further validation.
-
ABT-888 (Veliparib): PARP1/2 Research Guide
2026-09-10
ABT-888, also called Veliparib, is a selective PARP1/2 inhibitor used to study DNA repair inhibition and treatment sensitization. Its strongest dossier-supported applications are preclinical colorectal cancer research, combination chemotherapy, and radiation-response experiments rather than direct clinical treatment.